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SUMMARY STATEMENT 
Using genetic approaches, we reveal that during normal murine development the SHH pathway is first 
required for normal specification of Rathke’s pouch embryonic precursors and subsequently to control 
their proliferation.  
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ABSTRACT  
 
Sonic hedgehog (SHH) is an essential morphogenetic signal dictating cell fate decisions in several 
developing organs in mammals. In vitro data suggest that SHH is required to specify LHX3+/LHX4+ 
Rathke’s pouch (RP) progenitor identity. However, in vivo studies have failed to reveal such a 
function, supporting instead, a critical role for SHH in promoting proliferation of these RP progenitors 
and for differentiation of pituitary cell types. Here, we have used a genetic approach to demonstrate 
that activation of the SHH pathway is necessary to induce LHX3+/LHX4+ RP identity in mouse 
embryos. First, we show that conditional deletion of Shh in the anterior hypothalamus results in a 
fully penetrant phenotype characterised by a complete arrest of RP development, with lack of 
Lhx3/Lhx4 expression in RP epithelium at 9.0 dpc (days post coitum) and total loss of pituitary tissue 
by 12.5 dpc. Conversely, over-activation of the SHH pathway by conditional deletion of Ptch1 in RP 
progenitors leads to severe hyperplasia and enlargement of the Sox2+ve stem cell compartment by the 
end of gestation.  
  
	 4	
INTRODUCTION 
Together, the pituitary gland and hypothalamus serve as the main regulator of the neuroendocrine 
axis, controlling critical physiological processes such as growth, reproduction, metabolism and stress 
response. The vertebrate pituitary is comprised of the anterior pituitary (AP), including the anterior 
and intermediate lobes (AL and IL, respectively), and the posterior pituitary (PP). The AP derives 
from Rathke’s pouch (RP), a dorsal elevation of the oral ectoderm near the boundary with the 
pharyngeal endoderm, whilst the PP is of neural origin and originates from a recess of the overlying 
hypothalamus, the presumptive infundibulum (Davis and Camper, 2007; Rizzoti, 2015; Takuma et al., 
1998; Treier et al., 1998). Progenitors in the periluminal epithelium of RP proliferate rapidly from 
12.5 to 14.5 dpc, to subsequently exit the cell cycle and initiate cell-lineage commitment and 
differentiation into the different hormone-producing cells (Bilodeau et al., 2009; Davis et al., 2011). 
The AP contains six main hormone-secreting cell types: somatotrophs, (growth hormone, GH), 
lactotrophs, (prolactin, PRL), corticotrophs, (adrenocorticotropic hormone, ACTH), thyrotrophs, 
(thyroid stimulating hormone, TSH), gonadotrophs, (luteinising hormone, LH and follicle stimulating 
hormone, FSH) and melanotrophs (melanocyte-stimulating hormone, MSH). In addition, the AP 
contains Sox2+ve stem cells, which contribute to the postnatal expansion of the gland and organ 
homeostasis (Andoniadou et al., 2013; Rizzoti et al., 2013). The PP holds no endocrine cell types, but 
is instead richly endowed with axonal projections from hypothalamic neurons (Andersen & 
Rosenfeld, 2001; Castinetti et al, 2011; Kelberman et al., 2009). The function of the AP is primarily 
regulated by the parvocellular and magnocellular neurons, which reside in distinct nuclei in the 
hypothalamus (Andersen and Rosenfeld, 2001; Burbridge et al., 2016; Shimogori et al., 2010).  
  RP development is thought to be a step-wise process that requires at least two sequential 
inductive signals from the diencephalon (Takuma et al., 1998). First, BMP4 is required for induction 
and formation of a pouch rudiment and second, FGF8 signalling is necessary for activation of Lhx3 
and subsequent development of the pouch rudiment into a definitive RP (Takuma et al., 1998). 
Indeed, genetic evidence suggests that the acquisition of RP progenitor identity depends on the 
activation of Lhx3 and Lhx4 in the pouch rudiment epithelium at 9.0 dpc (Sheng et al., 1996; Sheng et 
al., 1997). Embryos homozygous null for Lhx3 and Lhx4 show early RP developmental arrest, where 
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only a rudimentary pouch is formed. No pituitary tissue is recognisable beyond 15.5 dpc, possibly due 
to decreased proliferation (Sheng et al., 1997) and/or increased apoptosis (Ellsworth et al., 2008; 
Raetzman et al., 2002; Zhao et al., 2006). Furthermore, double homozygous null embryos for Pitx1 
and Pitx2, two transcription factors expressed in the oral ectoderm and RP at 9.0 dpc, fail to activate 
Lhx3/Lhx4 expression, resulting in severe RP developmental arrest (Charles et al., 2005; Suh et al., 
2002).   
Several in vitro and in vivo studies have established a critical role for hypothalamic 
expression of BMP4 and FGFs for activation of Lhx3/Lhx4 expression in RP epithelium (Davis and 
Camper, 2007; Ericson et al., 1998a; Gleiberman et al., 1999; Norlin et al., 2000; Ohuchi et al., 2000; 
Ozone et al., 2016; Revest et al., 2001; Sbrogna et al., 2003; Suga et al., 2011; Takuma et al., 1998; 
Treier et al., 1998; Treier et al., 2001). In contrast, definitive in vivo evidence for a similar role of 
SHH is lacking. Genetic experiments in zebrafish and mouse have provided evidence supporting a 
role for Hedgehog signalling in the proliferation of LHX3+ve/LHX4+ve RP progenitors rather than in 
the initial induction of RP identity (i.e. activation of Lhx3 and Lhx4 expression) (Dutta et al., 2005; 
Herzog et al., 2003; Karlstrom et al., 1999; Park et al., 2000; Treier et al., 2001; Wang et al., 2010). 
Over-expression of the SHH inhibitor Hhip under the control the Pitx1 promoter does not prevent the 
activation of Lhx3/Lhx4 or formation of a definitive RP, but results in pituitary hypoplasia (Treier et 
al., 1998). Conversely, over-expression of Shh leads to pituitary hyperplasia, suggesting a 
proliferative role for SHH on already specified LHX3+ve/LHX4+ve RP progenitors. More recently, 
the anterior hypothalamic expression of Shh has been conditionally deleted using a specific SOX2-
binding enhancer-Cre (SBE2-Cre) (Zhao et al., 2012). This leads to mis-patterning of the 
hypothalamus and RP hypoplasia, but Lhx3/Lhx4 expression occurs in RP epithelium. In fact, in some 
embryos, multiple LHX3+ve/LHX4+ve pouches were observed. Genetic ablation in mice supports a 
critical role of Gli factors during hypothalamo-pituitary development but the exact mechanisms are 
still not fully clarified (Park et al., 2000; Wang et al., 2010). 
 In this manuscript, we have used genetic approaches in mouse to demonstrate that, in addition 
to promoting RP progenitor proliferation, hypothalamic Shh expression is essential for the initial 
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activation of Lhx3/Lhx4 transcription in RP epithelium and formation of a definitive pouch. In 
addition, we show that the anterior hypothalamus fails to differentiate. 
 
RESULTS 
 
The SHH pathway is active throughout normal pituitary development in mice and humans  
First, we performed a detailed study to assess the expression of Shh/SHH and its effector target genes 
Gli1 and Ptch1 throughout pituitary development in both mice and humans.  
At 9.5 and 10.5 dpc, Shh transcripts were detected within a rostral neural domain, including 
the developing anterior hypothalamus and ventral telencephalon, and a caudal domain, encompassing 
the posterior hypothalamus, possibly the mammillary area, and adjacent floorplate of the midbrain. 
There is a Shh-negative area between the mammillary region and anterior hypothalamus, likely 
corresponding to the tuberal hypothalamus (Fig. 1 A,B). At these stages, Shh expression was also 
observed in the pharyngeal endoderm immediately posterior to the developing RP, which was devoid 
of any Shh expression (Fig. 1 A,B). Although Shh expression was initially reported to be expressed in 
the oral ectoderm of wild-type embryos at 9.5-10.5 dpc (Treier et al., 1998; Treier et al., 2001), we 
could not detect the presence of Shh transcripts in this layer medially between 9.5 and 10.5 dpc, in 
agreement with a recent report (Zhao et al., 2012). To clarify further this discrepancy and assess the 
timing of Shh expression in the oral ectoderm, we performed a detailed expression analysis on 
histological sections of wildtype embryos from 16-46 somites (i.e. 9.0 to 11.5 dpc; (Hogan et al., 
1994) (Fig. S1). By staging the embryos by somite number, we aimed to accurately pin-point the 
onset of Shh expression in this tissue. This study revealed that Shh mRNA is first detected in the 
lateral oral ectoderm adjacent to the developing RP in 33 somite-stage embryos (10.0 dpc) (Fig. 
S1E¢¢). Strong expression in the lateral oral ectoderm was more evident at 42 and 46 somites (11-11.5 
dpc) (Fig. S1G¢¢,H-H¢¢ ). RNAScope in situ hybridisation, enabling sensitive detection of mRNA 
expression up to single molecule resolution, confirmed the absence of Shh expression in the oral 
ectoderm at 16 somites (Fig. S1A-A¢¢) (Wang et al., 2012). 
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Supporting the RNA expression pattern, SHH was strongly detected in the anterior 
hypothalamus, pharyngeal endoderm and a weak but consistent signal was also observed in the oral 
ectoderm and anterior part of RP epithelium, suggesting potential spreading of SHH from the pre-
optic area towards the developing RP (Fig. 1 G,H). From 11.5 to 14.5 dpc, Shh transcripts were 
detected within the developing hypothalamus (Fig. 1C-E,I-K) and by 18.5 dpc, signal was restricted 
to the ventricular zone of the 3rd ventricle (Fig. 1F). No obvious expression was detected in the 
developing pituitary by digoxigenin-labelled Shh riboprobes from 9.5-18.5 dpc (Fig. 1F). In contrast, 
SHH protein was clearly observed in single cells within the anterior pituitary at 18.5 dpc (Fig. 1L). In 
agreement with this, Shh transcripts were detected in sporadic single cells within the anterior pituitary 
at 18.5 dpc by RNAscope in situ hybridisation (Supp. Fig. 2A,B).  
To assess the activation of the SHH pathway, the expression of the target genes Gli1 and 
Ptch1 was analysed by in situ hybridisation. At 9.5 dpc, Gli1 transcripts were detected broadly 
throughout the developing hypothalamus and RP (Fig. 1M) and at 10.5 and 12.5 dpc, RP epithelium 
expressed Gli1 robustly (Fig. 1N-P). By 14.5 dpc, Gli1 transcripts were found mostly in the dorsal 
region of the periluminal epithelium of RP and by 18.5 dpc, expression was restricted to the marginal 
zone, a region of the anterior pituitary ventrally lining the cleft that is highly enriched for Sox2+ve 
stem cells (Fig. 1Q,R). However, in the hypothalamus, Gli1 expression could not be detected in the 
ventral midline of the anterior hypothalamus or developing infundibulum from 10.5 dpc onwards, but 
signal was strong in the posterior hypothalamus, possibly including the prospective caudal tuberal and 
mammillary area (Fig. 1N). At 18.5 dpc, Gli1 expression was restricted to the ventricular zone of the 
3rd ventricle (Fig. 1R). 
Ptch1 expression was also very dynamic. A 9.5 dpc, Ptch1 transcripts were weakly detected 
in the posterior (forming mammillary region), strongly detected in the anterior hypothalamus and 
barely detected in the tuberal hypothalamus - patterns that became even more pronounced by 10.5 dpc 
(Fig. 1S,T). Strong Ptch1 signal was detected in the hypothalamus from 11.5-14.5 dpc, except for the 
infundibulum, and by 18.5 dpc, the hypothalamic signal was mostly detected in the ventricular zone 
of the 3rd ventricle (Fig. 1U-X). Within the developing RP, Ptch1 expression was detected broadly in 
the epithelial progenitors at 9.5 dpc, but became progressively restricted to the ventral areas of RP, 
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adjacent to the oral epithelium and pharyngeal endoderm by 11.5 dpc (Fig. 1S-U). At 12.5 dpc, only a 
small region of the periluminal epithelium of RP was positive for Ptch1 transcripts (Fig. 1V). 
Subsequently, at 14.5 and clearly at 18.5 dpc, Ptch1 transcripts were observed only in the marginal 
zone (Fig. 1 W,X).  
At Carnegie stage 15 (CS15) in human fetal embryos, SHH transcripts and protein were 
identified in the anterior hypothalamus and pharyngeal endoderm, but were absent from the 
developing RP, similar to the mouse (Supp. Fig. 3A-D). GLI1 transcripts were observed throughout 
the developing hypothalamus (Supp. Fig. 3E,F) and RP, suggesting activation of the pathway.  
Together, these expression studies suggest that the SHH pathway is activated preferentially in 
regions containing undifferentiated precursors/stem cells, such as the RP periluminal epithelium at 
early stages of development and the marginal zone lining the cleft at 18.5 dpc. In addition, these 
analyses demonstrate the expression of SHH protein in tissues adjacent to the developing RP at early 
developmental stages, including the developing hypothalamus and pharyngeal endoderm suggesting 
that signalling from these domains may be required to activate the pathway in RP progenitors.  
 
Deletion of Shh in the Hesx1 cell lineage leads to pituitary aplasia in Hesx1Cre/+;Shhfl/- mutants  
The Hesx1-Cre mouse line drives Cre-mediated recombination in the anterior neural plate, including 
the prospective telencephalon and prospective anterior hypothalamus, as well as RP epithelium from 
9.0 dpc (Jayakody et al., 2012). We generated Hesx1Cre/+;Shhfl/- mice to study the consequences of 
early Shh deletion in the anterior hypothalamic area, as Shh is not expressed in RP epithelium and 
expression in the oral ectoderm occurs from 10.0 dpc.  
Genotypic analysis of embryos between 9.5 and 18.5 dpc revealed no statistical deviation 
from the expected Mendelian ratios (Table 1, n=361, Chi test p=0.9). In contrast, genotyping of pups 
of up to 3 weeks of age, revealed a significant deviation from the expected ratios (Table 1, n=67, Chi 
test p<0.001). No Hesx1Cre/+;Shhfl/- mice were identified postnatally, suggesting perinatal lethality. 
Hesx1Cre/+;Shhfl/-  mutant embryos showed mild forebrain defects from 10.5 dpc, including a 
reduction in the size of the telencephalic vesicles, and by 11.5 dpc, loss of pigmented retina (Fig. 
S4A-C). A very small proportion of the mutant embryos showed more severe defects, including 
	 9	
holoprosencephaly at 10.5 dpc (n=4 out of 28, Fig. S4D-F). At 18.5 dpc, severe craniofacial defects 
as well as telencephalic and hypothalamic abnormalities were observed in all mutants analysed (n=3, 
Fig. S5A-H). Pituitary tissue could not be identified morphologically at this stage in serial section 
analysis of the mutants (Fig. S5I-L).  
Immunostaining against GH and PIT1, which label most of the pituitary cells at 18.5 dpc, 
revealed the complete lack of expression in serial sections in Hesx1Cre/+;Shhfl/- mutants at 18.5 dpc 
(Fig. S6). To further characterise the observed pituitary aplasia, we analysed embryos from 9.5 dpc 
onwards by haematoxylin-eosin staining. At 9.5 dpc, control embryos showed a close association 
between the evaginating RP epithelium and the floor of the neuroepithelium of the prospective 
infundibular area (Fig. 2A). In contrast, this intimate association was often lost in Hesx1Cre/+;Shhfl/-  
mutant embryos and mesenchymal tissue was observed intercalated between RP and the neural 
epithelium and appeared to be over-grown (Fig. 2B). Reduced size and failure to contact the 
infundibular area was more obvious at 10.5 dpc and by 11.5 dpc, RP was severely hypoplastic and no 
infundibulum could be observed (Fig. 2 C-F). At 12.5 dpc, Hesx1Cre/+;Shhfl/-  mutant embryos 
displayed a fully penetrant phenotype in which RP was completely lost and no pituitary tissue could 
be identified from 12.5-18.5 dpc either by H&E or immunostaining (Fig. 2G,H, Fig. S5). RNA in situ 
hybridisation on serial histological sections of Hesx1Cre/+;Shhfl/- mutants at 18.5 dpc revealed the loss 
or severe reduction in expression of most of the hypothalamic factors controlling pituitary function, 
including Ghrh (growth hormone-releasing hormone), Ss (somatostatin), Ot (oxytocin), Avp (arginine 
vasopressin) and Gnrh (gonadotropin-releasing hormone) as well as Pomc1 (proopiomelanocortin-
alpha), suggesting loss of neuronal differentiation (Fig. 3).  
The genetic deletion of Shh in the Hesx1 cell lineage was assessed by RNA in situ 
hybridisation and immunofluorescence on histological sections of Hesx1Cre/+;Shhfl/- and control 
littermates at 9.5 to 10.5 dpc. While in the control embryos, Shh transcripts were observed in the 
anterior and posterior developing hypothalamus, no Shh expression was detectable in the anterior 
hypothalamus in Hesx1Cre/+;Shhfl/- mutants, despite the strong signal in the posterior hypothalamic area 
(Fig. 4A-F). At 10.5 dpc, Shh expression was not detected within the developing RP in control 
embryos, however, a weak but consistent signal was detected in the posterior region of the 
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evaginating RP in Hesx1Cre/+;Shhfl/- mutants, that can be interpreted as a rostral extension of the 
pharyngeal endoderm Shh expression domain into the developing RP (Fig. 4E,F). Loss of SHH in the 
anterior hypothalamus and ectopic SHH expression in the posterior RP were also confirmed at the 
protein level by specific immunofluorescence staining (Fig. 4G,H). In agreement with the deletion of 
Shh, expression of Ptch1 was lost in the anterior, yet present in the posterior hypothalamus in 
Hesx1Cre/+;Shhfl/- mutants (Fig. 4K,L). Loss of Ptch1 and Gli1 expression was also observed in the 
anterior region of the developing RP, with transcripts detectable only in the posterior RP (Fig. 4I-L). 
Expression of Shh was observed in the oral ectoderm of the Hesx1Cre/+;Shhfl/- mutants at 11.5 dpc, 
invading the epithelium of a rudimentary RP (Fig. 4M,N).  These results demonstrate that, in addition 
to severe hypothalamic, telencephalic and craniofacial defects at late gestation, the early loss of Shh 
expression in the anterior hypothalamus results in abnormal development of RP from 9.5 dpc with 
pituitary aplasia from 12.5 dpc. 
 
Anterior hypothalamus marker expression is lost in in Hesx1Cre/+;Shhfl/- mutants 
Fgf8 and Bmp4 are essential signals controlling hypothalamus and RP development (Davis 
and Camper, 2007; Ericson et al., 1998). Transcripts for these secreted factors were normally 
expressed in the posterior hypothalamus at 10.5 dpc, which includes the tuberal hypothalamus and 
primordium of the infundibulum, but their expression domains do not reach the anterior hypothalamic 
area, where Shh is expressed (Fig. 5A,C). In contrast, the expression domains of these critical 
hypothalamic signals were extended anteriorly in the Hesx1Cre/+;Shhfl/- mutants, invading the domain 
where Shh was detected in the control embryos (Fig. 5B,D). The expression domains of Tbx2 and 
Tbx3, two negative regulators of Shh expression (Trowe et al., 2013), were similar between 
Hesx1Cre/+;Shhfl/- mutants and controls, although Tbx3 expression domain appeared slightly expanded 
(Fig. 5E-H). Nkx2.1, another critical regulator of hypothalamic development (Kimura et al., 1996; 
Takuma et al., 1998), was broadly expressed throughout the hypothalamus in control embryos, but its 
expression domain was shortened in Hesx1Cre/+;Shhfl/- mutants with a lack of expression in the anterior 
hypothalamus (Fig. 5I,J). Otx2 is an important transcription factor required for normal development 
of the hypothalamus and pituitary (Acampora et al., 1995; Mortensen et al., 2015; Tajima et al., 
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2009). Immunostaining revealed OTX2 expression in the posterior hypothalamus, with a sharp 
boundary at the level where the infundibulum will develop, and the developing ventral telencephalon, 
with a negative region encompassing the anterior hypothalamus (Fig. 5Q). In contrast, in the 
Hesx1Cre/+;Shhfl/- mutants OTX2 domain was broadly observed throughout the hypothalamus with no 
detectable negative area in the neuroepithelium, suggesting that the anterior hypothalamus was 
missing (Fig. 5R). Expression analysis with other regional markers including TCF4, Islet1 and Wnt5a 
as well as Pomc1, a marker of arcuate neurons, further demonstrated the loss of the anterior 
hypothalamus in Hesx1Cre/+;Shhfl/- mutants (Fig. 5K-P,S-X). Loss of ACTH and TPIT neural 
expression was observed in the anterior hypothalamus of the mutants at 12.5 dpc (Fig. S7). Together, 
these analyses indicate a loss of expression of anterior hypothalamic markers concomitant with the 
rostral expansion of the expression domain of posterior hypothalamic markers in Hesx1Cre/+;Shhfl/- 
mutants.  
 
Loss of Lhx3 and Lhx4 expression in RP epithelium in Hesx1Cre/+;Shhfl/- mutants 
Embryos homozygous null for Lhx3 and Lhx4 show arrested RP development with absence of 
pituitary tissue by 15.5 dpc (Sheng et al., 1997), a phenotype very similar to that in Hesx1Cre/+;Shhfl/- 
mutants. Indeed, neither Lhx3 nor Lhx4 expression were detected in RP in Hesx1Cre/+;Shhfl/- mutants, 
either by in situ hybridisation or immunostaining from 9.0 dpc (16 somites) to 11.5 dpc (Fig. 6A-
D,G,H,K,L,M-P). Despite the failure to activate Lhx3 and Lhx4 expression, other RP markers such as 
PITX1, SOX2, Pitx2, Pax6, Six3, Islet1 and Wnt4 were found to be expressed in the developing RP in 
Hesx1Cre/+;Shhfl/- mutants with no apparent differences compared to control embryos (Fig. 6E,F,I,J,Q-
X and Fig. 4S,T,W,X).  
The loss of pituitary tissue in Lhx3-/-;Lhx4-/- double mutants has been attributed to decreased 
proliferation and/or increased apoptosis of RP progenitors. Immunostaining against activated 
Caspase-3, a marker of apoptotic cells (Wolf et al., 1999), revealed the presence of only a few 
scattered positive cells in RP at 11.5 dpc, and none at 9.5 or 10.5 dpc (Fig. 7H-M). A small but 
significant decrease in the mitotic index, as assessed using the mitotic marker phospho-histone H3 
(Hendzel et al., 1997), was observed in Hesx1Cre/+;Shhfl/- mutants at 11.5 dpc (Fig. 7A-G). Of note, 
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comparable values were observed between mutants and control embryos at 9.5 and 10.5 dpc, 
suggesting that decreased proliferation may not be the only mechanism accounting for the pituitary 
aplasia observed in the Hesx1Cre/+;Shhfl/- mutants from 12.5 dpc. 
Hypothalamic BMP4 and FGF8 signals are important to induce LHX3+ve/LHX4+ve RP 
progenitor identity (Treier et al., 1998; Treier et al., 2001). As shown in Fig. 5A-D, the hypothalamic 
expression domains of these factors were anteriorised in Hesx1Cre/+;Shhfl/- mutants at 10.5 dpc, a 
phenotype usually associated with increased recruitment of additional oral ectoderm into RP 
epithelium leading to RP enlargement or even the induction of multiple LHX3+/LHX4+ pouches 
(Dasen et al., 2001; Davis and Camper, 2007; Gaston-Massuet et al., 2016; Zhao et al., 2012). 
Therefore, it was interesting that even in the presence of more FGF and BMP signalling, RP 
development still arrested. Activation of the BMP and FGF pathways was demonstrated by the 
expression of p-SMAD1/5/8 and p-ERK1/2 in RP epithelium in Hesx1Cre/+;Shhfl/- mutants and control 
embryos at 10.5 dpc, respectively (Fig. S8C,D,G,H). In addition, Sprouty2 (Spry2), a target gene of 
the FGF pathway (Minowada et al., 1999; Tefft et al., 1999), was expressed in the mutant RP at this 
stage, suggesting pathway activation (Fig. S8A,B). Expression of Fgfr2, which mediates FGF8 and 
FGF10 signalling (Turner and Grose, 2010), was also detected in the mutant RP (Fig. S8A,B). These 
results suggest that both the FGF and BMP signalling pathways are activated in the Hesx1Cre/+;Shhfl/- 
mutant RP, excluding the possibility that the lack of Lhx3 and Lhx4 expression is due to the inability 
of RP epithelium to respond to these signals. In addition, these analyses demonstrate that the FGF and 
BMP pathways are not sufficient to induce LHX3+ve/LHX4+ve RP identity in the absence of SHH 
signalling. 
 
A change of fate of RP epithelium into oral ectoderm and pharyngeal endoderm contributes to 
the loss of pituitary tissue in Hesx1Cre/+;Shhfl/- mutants 
We observed that markers normally expressed in either the oral ectoderm or pharyngeal 
endoderm, abutting the developing RP, were ectopically expressed and invaded the epithelium of the 
evaginating mutant RP. For example, Bmp4 expression was detected in the oral epithelium but did not 
invade the anterior region of RP in control embryos at 10.5 dpc (Fig. 5C). However, ectopic Bmp4 
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expression was consistently observed in the anterior region of RP in Hesx1Cre/+;Shhfl/- mutants, 
suggesting a caudal extension of the Bmp4+ve oral ectoderm into the developing pouch (Fig. 5D). 
Likewise, the expression of TCF4 (Fig. 5O) and SHH (Fig. 4E,G) was detected in the pharyngeal 
endoderm, but not in RP in control embryos at 10.5 dpc. In contrast, an anterior expansion of both 
TCF4 and SHH expression domain was observed in the Hesx1Cre/+;Shhfl/- mutants, with strong signal 
detectable in the posterior region of RP adjacent to the pharyngeal endoderm (Fig. 5P, Fig. 4F, H). 
Finally, these observations were further corroborated with other markers, such as N- and E-cadherin. 
In normal embryos at 10.5 dpc, E-cadherin is expressed in the oral ectoderm, pharyngeal endoderm 
but not in RP, which expresses N-cadherin (Fig. 5U). Anterior N-cadherin expression was lost in the 
Hesx1Cre/+;Shhfl/- mutant RP, which expressed E-cadherin (Fig. 5V). Similar ectopic expression was 
also revealed by immunostaining against Islet1, which was only identified in the ventral region of RP 
in control embryos, but throughout RP in Hesx1Cre/+;Shhfl/- mutants (Fig. 5S,T).  
To further characterise the loss of RP progenitor identity, we performed gene expression 
analysis by RNA sequencing of manually dissected RP from Hesx1Cre/+;Shhfl/- mutant and control 
embryos at 10.5 dpc (n=2 RP per genotype). This study revealed a total of 208 significant 
differentially expressed genes between genotypes (adjusted p-value <0.1; Fig. S9A). Gene ontology 
analysis presented the term GO: 0029183 “Pituitary gland development” as a term significantly 
associated to these dysregulated genes (adjusted p-value <0.05; Table S1). Heatmap representation of 
expression levels of 12 genes involved in normal pituitary development revealed a significant down-
regulation of Lhx3, Lhx4, Hesx1, Prop1 and Six3 expression in the mutant relative to the control RP 
(Fig. S9B; Table S2). Furthermore, gene set enrichment analysis revealed a negative enrichment of 
genes associated with an active SHH pathway in the mutant relative to control RP (normalised 
enrichment score, NES = -1.73, false discovery rate, FDR = 0.008), demonstrating a down-regulation 
of the pathway in the Hesx1Cre/+;Shhfl/- mutant RP, also supported by the Heatmap representation of 
SHH pathway genes (Fig. S9C,D ). Shh mRNA was found to be non-significantly down-regulated in 
the Hesx1Cre/+;Shhfl/- mutant RP (2.57 fold change, adjusted p-value 0.236), possibly reflecting the 
Cre-mediated deletion of the Shh locus.    
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Together, these analyses strongly suggest that the loss of Shh expression in the anterior 
hypothalamus results in failure to activate the SHH pathway and to initiate Lhx3/Lhx4 expression in 
the RP epithelium. This may result in a progressive cell fate transformation of RP epithelium, 
whereby the rostral part of RP acquires a non-RP oral ectoderm fate whilst its posterior aspect turns 
into pharyngeal endoderm by 12.5 dpc.  
  
Conditional over-activation of the SHH pathway leads to severe pituitary hyperplasia but 
normal differentiation of hormone-producing cells in Hesx1Cre/+;Ptch1fl/fl  mutants 
We sought to explore the consequences of over-activating the pathway during hypothalamic-pituitary 
axis development by genetically deleting Ptch1 in the Hesx1-cell lineage in Hesx1Cre/+;Ptch1fl/fl mice.  
Hesx1Cre/+;Ptch1fl/fl mice die perinatally (Table 2) with severe forebrain and craniofacial 
defects (Fig. S10). Haematoxylin-eosin staining revealed no gross morphological defects in the 
developing RP or infundibulum between Hesx1Cre/+;Ptch1fl/fl mutants and control embryos at 10.5 dpc 
(Fig. 8A,B). The first clear evidence of a morphological defect was observed at 12.5 dpc (Fig. 8C,D), 
when the developing anterior lobe appeared hyperplastic in Hesx1Cre/+;Ptch1fl/fl mutants compared 
with controls. Pituitary hyperplasia was more evident at 14.5 and 18.5 dpc, with an enlargement of the 
cleft and thickening of the anterior lobe in mutants relative to controls (Fig. 8E-H). Up-regulation of 
the SHH pathway in RP was observed from 10.5 dpc (Fig. 8I-P. Cell counting of dissociated 
pituitaries at 18.5 dpc showed a total of 98,333 ± 4% cells in the pituitary of the Hesx1Cre/+;Ptch1fl/fl 
versus 48,600 ± 9.4% (p<0.01) in the controls, confirming the hyperplasia.  
Quantitative analysis of mitotic cells, revealed a significant increase in the mitotic index in 
the periluminal progenitors lining RP at 12.5 and 14.5 dpc, and cells around the pituitary cleft at 18.5 
dpc in the Hesx1Cre/+;Ptch1fl/fl mutants relative to the controls (Fig. S11). Patterning of the developing 
hypothalamus and specification of RP at 10.5 dpc occurred normally in Hesx1Cre/+;Ptch1fl/fl  mutants 
compared with control embryos (Fig. S12). Likewise, cell commitment and differentiation of 
hormone-producing cells was not prevented in the Hesx1Cre/+;Ptch1fl/fl   mutants (Fig. S13 and S14).  
 
	 15	
Over-activation of the SHH pathway results in expansion of the Sox2+ve stem cell compartment 
in Hesx1Cre/+;Ptch1fl/fl mutants 
At 14.5 dpc, the expression pattern of SOX2 was comparable between genotypes (Fig. 9A, 
B). In contrast, SOX9 expression in the developing AL appeared elevated in the Hesx1Cre/+;Ptch1fl/fl   
mutants compared with controls (Fig. 9E,F). At 18.5 dpc, numbers of SOX2 and SOX9+ve cells were 
significantly increased in the anterior pituitary and marginal zone of Hesx1Cre/+;Ptch1fl/fl   embryos 
compared with controls (Fig. 9C, D, G-I). It has previously been shown that pituitary cells with 
clonogenic potential in vitro are contained within the SOX2+ve cell population (Andoniadou et al., 
2012; Andoniadou et al., 2013; Vankelecom, 2010). Culture of dissociated cells in stem-cell 
promoting media revealed a significant increase in clonogenic potential of the Hesx1Cre/+;Ptch1fl/fl 
mutant pituitaries  compared with controls at 18.5 dpc, evidenced by a 7-fold increase in numbers of 
clonogenic cells (Fig. 9J). Together, these studies demonstrate that the activation of the SHH pathway 
by Ptch1 deletion in Hesx1Cre/+;Ptch1fl/fl  mutants results in increase proliferation of 
LHX3+ve/LHX4+ve RP progenitors resulting in  anterior pituitary hyperplasia and enlargement of 
the stem cell compartment at 18.5 dpc. 
 
DISCUSSION   
The main finding in this paper is the demonstration that SHH signalling is essential for the 
specification of LHX3+ve;LHX4+ve RP progenitors in vivo. In vitro, both in explant cultures of 
prospective RP oral epithelium (Treier et al., 2001) as well as embryonic stem cell aggregates (Ozone 
et al., 2016; Suga et al., 2011), SHH signals or the activation of this pathway using smoothened 
agonists is required for the specification of LHX3+ve progenitors. However, genetic approaches have 
failed to unravel this function, perhaps because the inhibition of the SHH pathway in the developing 
pituitary was not achieved early enough (Treier et al., 2001) or the deletion of the Shh expression in 
the anterior hypothalamus was incomplete (Zhao et al., 2012). Here, we show that the loss of SHH 
expression in the anterior hypothalamus in Hesx1Cre/+;Shhfl/-  embryos leads to down-regulation of the 
pathway and failure to activate the expression of LHX3 and LHX4 in the rudimentary RP epithelium 
at 9.0 dpc (i.e. 16 somite stage). As a consequence, there is a severe developmental arrest, no 
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formation of a definitive pouch and loss of pituitary tissue by 12.5 dpc, a phenotype resembling that 
of the Lhx3-/-;Lhx4-/- double homozygous mutants (Sheng et al., 1996; Sheng et al., 1997). These 
morphological and molecular defects observed in Hesx1Cre/+;Shhfl/- mutants are also present in mouse 
mutants with disrupted BMP and FGF signalling, either due to loss/reduction of Bmp and Fgf 
expression in the hypothalamus or defective competence of RP to respond to hypothalamic BMP and 
FGF signals (De Moerlooze et al., 2000; Kimura et al., 1996; Ohuchi et al., 2000; Takuma et al., 
1998). Being required does not necessarily mean that SHH is sufficient to induce RP specification, as 
the expansion of hypothalamic Shh expression in Nkx2.1-/- mutants does not induce Lhx3 or Lhx4 
expression in the evaginating RP in the absence of normal BMP and FGF signalling (Fig. 10). Of 
note, Nkx2.1 is primarily required within the hypothalamus for normal RP development (Takuma et 
al., 1998). Therefore, BMP, FGF and SHH are all required to induce RP progenitor fate at 9.5 dpc and 
cannot replace each other.  
Our results demonstrate that the anterior hypothalamic expression of Shh is essential for 
normal patterning of the hypothalamus and potentially, these hypothalamic defects (i.e. up-regulation 
of Tbx2 and Tbx3 and reduction of Wnt5a and TCF4 expression) could contribute to the RP 
phenotype. Shh is expressed in the anterior endoderm (prechordal plate) at neural plate stages where it 
plays a role in patterning the ventral midline and in the separation of the eye fields as well as the 
telencephalic vesicles (Xavier et al., 2016). In Hesx1Cre/+;Shhfl/- mutants, holoprosencephaly is 
infrequent and cyclopia is not observed, suggesting that signalling from the anterior endoderm is not 
compromised in the vast majority of the embryos. Although speculative, the excess of mesenchyme 
observed between the oral ectoderm and the anterior hypothalamus may interfere with signalling 
between the neural and oral ectoderm or have stimulatory or inhibitory effects that could also 
contribute to the phenotype. The reasons underlying the excess of mesenchyme are not known, but 
this defect may be related to the mis-patterning of the anterior hypothalamus (loss of Shh and ectopic 
Fgf8/10 and Bmp4 expression). Although we cannot rule out a contribution of other dysregulated 
signals, the fact that Gli1 and Ptch1 expression in the developing RP is down-regulated in 
Hesx1Cre/+;Shhfl/- mutants supports a direct role for the SHH pathway in RP specification. 
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The accompanying paper by Travis et al., provides further insights into the potential 
mechanism underlying the loss of anterior hypothalamic tissue in the absence of SHH signals. 
Inhibition of the SHH pathway using cyclopamine in chick embryos at HH10-13 (10-15 somites) 
results in failure to form the anterior hypothalamus (Six3+ve;Fgf10-ve neuroepithelium), and instead 
Six3+ve;Fgf10+ve progenitors stay in the tuberal region, which in chick, is expanded in 
thickness. This observation is very similar to our results in Hesx1Cre/+;Shhfl/- mutants (Fgf8 and Fgf10 
are co-expressed in the posterior hypothalamus in mice; Fig. S15; Treier et al., 1998; Treier et al., 
2001) and compatible with the phenotype observed by Zhao et al., 2012 where it was proposed that 
anterior hypothalamic SHH expression is essential to maintain critical gene expression boundaries 
along the antero-posterior axis of the midline hypothalamus. In addition, in Travis et al., the inhibition 
of the SHH pathway by using cyclopamine results in failure to induce LHX3+ve RP progenitor 
identity, recapitulating our murine data and in agreement with experiments in zebrafish (Sbrogna et 
al., 2003).   
Analyses of the Ptch1-deleted mutants support the idea that the SHH pathway promotes cell 
proliferation of LHX3+ve/LHX4+ve RP progenitors during pituitary development. Of note, we failed 
to identify increased proliferation at 11.5 dpc, suggesting that persistent proliferation of RP 
progenitors becomes apparent at developmental stages when they begin to exit the cell cycle and 
initiate differentiation (i.e. beyond 13.5-14.5 dpc) (Bilodeau et al., 2009; Davis et al., 2011). The 
consequence of maintained proliferation in periluminal progenitors beyond 14.5 dpc is the expansion 
of differentiated pituitary cells as well as the Sox2+ve stem cells. This finding is in agreement with in 
vitro data reported recently (Pyczek et al., 2016). 
 In conclusion, our data support the mainstream role of the SHH pathway in the control of cell 
proliferation during pituitary development and in addition, have revealed an essential role for SHH in 
the specification of RP progenitors in vivo. 
 
MATERIALS AND METHODS 
 
Mice and human pituitaries 
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The Hesx1Cre/+, Shhfl/fl or Ptch1fl/fl mice have been described previously (Andoniadou et al., 2007; 
Uhmann et al., 2007). Shhfl/fl mice were obtained from the Jackson Laboratory (B6;129-
Shhtm2Amc/J). All mouse experiments were performed with Home Office and local ethical approval. 
Human embryonic samples were provided by the Joint MRC/Wellcome Trust (099175/Z/12/Z) 
Human Developmental Biology Resource. For further details, supplementary Materials and Methods. 
 
Histology and in situ hybridisation on histological sections 
Histological sections were stained using Harris’ haematoxylin for morphology as previously 
described (Andoniadou et al., 2011). In situ hybridisation was performed on paraffin-embedded 
histological sections as previously described (Sajedi et al., 2013). For further details, supplementary 
Materials and Methods. 
 
Cell counting in vivo 
Cell counts in vivo were performed in 4-6 non-consecutive histological sections immunostained with 
antibodies. pHH3, SOX2 and SOX9 expressing cells were calculated from the percentage of 
positively stained cells as a proportion of the total DAPI positive nuclei. A total of 1000-5000 DAPI 
positive cells and 100-1000 marker-positive cells were counted for each genotype. Analysis of SOX2 
and SOX9 positive cells was assessed through determining the relative proportion of marker-positive 
cells to total DAPI positive nuclei in a section. These proportions were then applied to average cell 
counts of dissociated pituitaries to determine an approximate absolute number of these cell 
populations in the pituitary.   
 
Immunofluorescence and RNAScope in situ hybridisation 
Section immunostaining was performed as previously described (Andoniadou et al., 2013). 
RNAScope in situ hybridisation was performed according to the manufacturer’s protocol (Wang et 
al., 2012) with conditions adapted for mouse embryos (Lodge et al., 2016). Embryos were formalin-
fixed prior to processing and histological sections were cut at 5µm thickness. The Shh mouse specific 
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probe, reagents and equipment were obtained from Advanced Cell Diagnostics. For further details, 
supplementary Materials and Methods. 
 
RNA sequencing of dissected Rathke’s pouch epithelium 
RP were manually dissected from mutant and control embryos at 10.5 dpc (n=2 for each genotype). 
RNA sequencing was performed at the Wellcome Trust Genomics Unit, Oxford University. The data 
have been deposited in ArrayExpress (EMBL-EBI, Hinxton), accession number: E-MTAB-5822. For 
further details, supplementary Materials and Methods. 
 
Assessment of clonogenic potential  
Clonogenic assays were performed on murine anterior pituitaries as previously described 
(Andoniadou et al., 2012; Andoniadou et al., 2013). For further details, supplementary Materials and 
Methods. 
  
Statistics 
Mendelian ratios were calculated using the chi-squared test. Clonogenic potential of 18.5 dpc 
pituitaries and total cells counts in vivo were evaluated using an un-paired t-test.   
 
 
ACKNOWLEDGMENTS 
We thank the Developmental Studies Hybridoma Bank (University of Iowa) and the National 
Hormone and Peptide Program (Harbor-University of California, Los Angeles Medical Center) for 
providing some of the antibodies used in this study. The human embryonic and fetal material was 
provided by the Joint Medical Research Council (MRC)/Wellcome Trust Human Developmental 
Biology Resource (www.hdbr.org) (Grant 099175/Z/12/Z). This work was supported by the Medical 
Research Council (MRC) (Grants MR/M000125/1 and MR/L016729/1), Great Ormond Street 
Hospital for Children Charity/Children with Cancer UK (GOSHCC/CWCUK) (Grant W1055) and by 
the National Institute for Health Research Biomedical Research Centre at Great Ormond Street 
Hospital for Children National Health Service Foundation Trust and University College London. G.C. 
	 20	
was recipient of a Child Health Research Appeal Trust (CHRAT) PhD fellowship. J.P.M.-B. is a 
Great Ormond Street Hospital Children’s Charity Principal Investigator. 
  
COMPETING INTERESTS 
The other authors declare no competing interests. 
 
AUTHOR CONTRIBUTIONS 
G.C designed and performed the experiments and wrote the paper. J.A. performed the bioinformatics 
analysis. L.P., S.H. and J.M.G.-M., genotyped mice, performed in situ hybridisation and 
immunostaining. E.L. performed the RNAScope in situ hybridisation. H.H. provided the Ptch1-flox 
mouse line. C.L.A. designed the experiments and overviewed the project. J.P.M.-B. designed the 
experiments, overviewed the project and wrote the paper. 
 
FUNDING 
Medical Research Council (MRC) (Grants MR/M000125/1 and MR/L016729/1). 
National Institute for Health Research Biomedical Research Centre at Great Ormond Street Hospital 
for Children National Health Service Foundation Trust and University College London. 
Great Ormond Street Hospital for Children Charity/Children with Cancer UK (GOSHCC/CWCUK) 
(Grant W1055) 
 
REFERENCES 
 
Acampora, D., Mazan, S., Lallemand, Y., Avantaggiato, V., Maury, M., Simeone, A. and Brûlet, 
P. (1995). Forebrain and midbrain regions are deleted in Otx2-/- mutants due to a defective 
anterior neuroectoderm specification during gastrulation. Development 121, 3279–90. 
Andersen, B. and Rosenfeld, M. G. (2001). POU domain factors in the neuroendocrine system: 
lessons from developmental biology provide insights into human disease. Endocr. Rev. 22, 2–35. 
Andoniadou, C. L., Signore, M., Sajedi, E., Gaston-Massuet, C., Kelberman, D., Burns, A. J., 
Itasaki, N., Dattani, M. and Martinez-Barbera, J. P. (2007). Lack of the murine homeobox 
gene Hesx1 leads to a posterior transformation of the anterior forebrain. Development 134, 
1499–1508. 
Andoniadou, C. L., Signore, M., Young, R. M., Gaston-Massuet, C., Wilson, S. W., Fuchs, E. 
	 21	
and Martinez-Barbera, J. P. (2011). HESX1- and TCF3-mediated repression of Wnt/ B-
catenin targets is required for normal development of the anterior forebrain. Development 4942, 
4931–4942. 
Andoniadou, C. L., Gaston-Massuet, C., Reddy, R., Schneider, R. P., Blasco, M. a, Le Tissier, 
P., Jacques, T. S., Pevny, L. H., Dattani, M. T., Martinez-Barbera, J. P., et al. (2012). 
Identification of novel pathways involved in the pathogenesis of human adamantinomatous 
craniopharyngioma. Acta Neuropathol. 
Andoniadou, C. L., Matsushima, D., Mousavy-gharavy, S. N., Signore, M., Mackintosh, A. I., 
Schaeffer, M., Gaston-massuet, C., Mollard, P., Jacques, T. S., Tissier, P. Le, et al. (2013). 
The Sox2 + population of the adult murine pituitary includes progenitor / stem cells with 
tumour-inducing potential. Cell Stem Cell. 
Bilodeau, S., Roussel-Gervais, A. and Drouin, J. (2009). Distinct developmental roles of cell cycle 
inhibitors p57Kip2 and p27Kip1 distinguish pituitary progenitor cell cycle exit from cell cycle 
reentry of differentiated cells. Mol. Cell. Biol. 29, 1895–908. 
Burbridge, S., Stewart, I. and Placzek, M. (2016). Development of the Neuroendocrine 
Hypothalamus. Compr. Physiol. 6, 623–43. 
Castinetti, F., Davis, S. W., Brue, T. and Camper, S. a (2011). Pituitary stem cell update and 
potential implications for treating hypopituitarism. Endocr. Rev. 32, 453–471. 
Charles, M. A., Suh, H., Hjalt, T. A., Drouin, J., Camper, S. A. and Gage, P. J. (2005). PITX 
genes are required for cell survival and Lhx3 activation. Mol. Endocrinol. 19, 1893–903. 
Dasen, J. S., Martinez Barbera, J. P., Herman, T. S., Connell, S. O., Olson, L., Ju, B., Tollkuhn, 
J., Baek, S. H., Rose, D. W. and Rosenfeld, M. G. (2001). Temporal regulation of a paired-like 
homeodomain repressor/TLE corepressor complex and a related activator is required for 
pituitary organogenesis. Genes Dev. 15, 3193–207. 
Davis, S. W. and Camper, S. a (2007). Noggin regulates Bmp4 activity during pituitary induction. 
Dev. Biol. 305, 145–160. 
Davis, S. W., Mortensen, A. H. and Camper, S. a (2011). Birthdating studies reshape models for 
pituitary gland cell specification. Dev. Biol. 352, 215–227. 
De Moerlooze, L., Spencer-Dene, B., Revest, J. M., Hajihosseini, M., Rosewell, I. and Dickson, 
C. (2000). An important role for the IIIb isoform of fibroblast growth factor receptor 2 (FGFR2) 
in mesenchymal-epithelial signalling during mouse organogenesis. Development 127, 483–92. 
Dutta, S., Dietrich, J.-E., Aspöck, G., Burdine, R. D., Schier, A., Westerfield, M. and Varga, Z. 
M. (2005). Pitx3 Defines an Equivalence Domain for Lens and Anterior Pituitary Placode. 
Development 132, 1579–1590. 
Ellsworth, B. S., Butts, D. L. and Camper, S. A. (2008). Mechanisms underlying pituitary 
hypoplasia and failed cell specification in Lhx3-deficient mice. Dev. Biol. 313, 118–129. 
Ericson, J., Norlin, S., Jessell, T. M. and Edlund, T. (1998). Integrated FGF and BMP signaling 
controls the progression of progenitor cell differentiation and the emergence of pattern in the 
embryonic anterior pituitary. Development 125, 1005–15. 
	 22	
Gaston-Massuet, C., McCabe, M. J., Scagliotti, V., Young, R. M., Carreno, G., Gregory, L. C., 
Jayakody, S. A., Pozzi, S., Gualtieri, A., Basu, B., et al. (2016). Transcription factor 7-like 1 is 
involved in hypothalamo–pituitary axis development in mice and humans. Proc. Natl. Acad. Sci. 
113, E548–E557. 
Gleiberman,  a S., Fedtsova, N. G. and Rosenfeld, M. G. (1999). Tissue interactions in the 
induction of anterior pituitary: role of the ventral diencephalon, mesenchyme, and notochord. 
Dev. Biol. 213, 340–353. 
Hendzel, M. J., Wei, Y., Mancini, M. A., Van Hooser, A., Ranalli, T., Brinkley, B. R., Bazett-
Jones, D. P. and Allis, C. D. (1997). Mitosis-specific phosphorylation of histone H3 initiates 
primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion 
coincident with mitotic chromosome condensation. Chromosoma 106, 348–60. 
Herzog, W., Zeng, X., Lele, Z., Sonntag, C., Ting, J.-W., Chang, C.-Y. and Hammerschmidt, M. 
(2003). Adenohypophysis formation in the zebrafish and its dependence on sonic hedgehog. 
Dev. Biol. 254, 36–49. 
Hogan, B.L., R., B., Constantini, F., Lacy, E. (1994). Manipulating the mouse embryo, a laboratory 
manual. Cold Spring Harbor Laboratory Press second edition, pages 24-25. 
Jayakody, S. A., Andoniadou, C. L., Gaston-massuet, C., Signore, M., Cariboni, A., Bouloux, P. 
M., Tissier, P. Le, Pevny, L. H., Dattani, M. T. and Martinez-barbera, J. P. (2012). SOX2 
regulates the hypothalamic-pituitary axis at multiple levels. J. Clin. Invest. 122, 3635–3646. 
Karlstrom, R. O., Talbot, W. S. and Schier, A. F. (1999). Comparative synteny cloning of zebrafish 
you-too: mutations in the Hedgehog target gli2 affect ventral forebrain patterning. Genes Dev. 
13, 388–93. 
Kelberman, D., Rizzoti, K., Lovell-Badge, R., Robinson, I. C. a F. and Dattani, M. T. (2009). 
Genetic regulation of pituitary gland development in human and mouse. Endocr. Rev. 30, 790–
829. 
Kimura, S., Hara, Y., Pineau, T., Fernandez-Salguero, P., Fox, C. H., Ward, J. M. and 
Gonzalez, F. J. (1996). The T/ebp null mouse: thyroid-specific enhancer-binding protein is 
essential for the organogenesis of the thyroid, lung, ventral forebrain, and pituitary. Genes Dev. 
10, 60–9. 
Lodge, E. J., Russell, J. P., Patist, A. L., Francis-West, P. and Andoniadou, C. L. (2016). 
Expression Analysis of the Hippo Cascade Indicates a Role in Pituitary Stem Cell Development. 
Front. Physiol. 7, 114. 
Minowada, G., Jarvis, L. A., Chi, C. L., Neubüser, A., Sun, X., Hacohen, N., Krasnow, M. A. 
and Martin, G. R. (1999). Vertebrate Sprouty genes are induced by FGF signaling and can 
cause chondrodysplasia when overexpressed. Development 126, 4465–75. 
Mortensen, A. H., Schade, V., Lamonerie, T. and Camper, S. A. (2015). Deletion of OTX2 in 
neural ectoderm delays anterior pituitary development. Hum. Mol. Genet. 24, 939–53. 
Norlin, S., Nordström, U. and Edlund, T. (2000). Fibroblast growth factor signaling is required for 
the proliferation and patterning of progenitor cells in the developing anterior pituitary. Mech. 
Dev. 96, 175–182. 
	 23	
Ohuchi, H., Hori, Y., Yamasaki, M., Harada, H., Sekine, K., Kato, S. and Itoh, N. (2000). FGF10 
Acts as a Major Ligand for FGF Receptor 2 IIIb in Mouse Multi-Organ Development. Biochem. 
Biophys. Res. Commun. 277, 643–649. 
Ozone, C., Suga, H., Eiraku, M., Kadoshima, T., Yonemura, S., Takata, N., Oiso, Y., Tsuji, T. 
and Sasai, Y. (2016). Functional anterior pituitary generated in self-organizing culture of human 
embryonic stem cells. Nat. Commun. 7, 10351. 
Park, H. L., Bai, C., Platt, K. A., Matise, M. P., Beeghly, A., Hui, C. C., Nakashima, M., Joyner, 
A. L., Alexandre, C., Jacinto, A., et al. (2000). Mouse Gli1 mutants are viable but have defects 
in SHH signaling in combination with a Gli2 mutation. Development 127, 1593–605. 
Pyczek, J., Buslei, R., Schult, D., Hölsken, A., Buchfelder, M., Heß, I., Hahn, H., Uhmann, A., 
Hooper, J. E., Scott, M. P., et al. (2016). Hedgehog signaling activation induces stem cell 
proliferation and hormone release in the adult pituitary gland. Sci. Rep. 6, 24928. 
Raetzman, L. T., Ward, R. and Camper, S. A. (2002). Lhx4 and Prop1 are required for cell 
survival and expansion of the pituitary primordia. Development 129, 4229–39. 
Revest, J.-M., Spencer-Dene, B., Kerr, K., De Moerlooze, L., Rosewell, I. and Dickson, C. 
(2001). Fibroblast Growth Factor Receptor 2-IIIb Acts Upstream of Shh and Fgf4 and Is 
Required for Limb Bud Maintenance but Not for the Induction of Fgf8, Fgf10, Msx1, or Bmp4. 
Dev. Biol. 231, 47–62. 
Rizzoti, K. (2015). Genetic regulation of murine pituitary development. J. Mol. Endocrinol. 54, R55–
73. 
Rizzoti, K., Akiyama, H. and Lovell-Badge, R. (2013). Mobilized Adult Pituitary Stem Cells 
Contribute to Endocrine Regeneration in Response to Physiological Demand. Cell Stem Cell 13, 
419–432. 
Sajedi, E., Gaston-Massuet, C., Signore, M., Andoniadou, C. L., Kelberman, D., Castro, S., 
Etchevers, H. C., Gerrelli, D., Dattani, M. T. and Martinez-Barbera, J. P. (2013). Analysis 
of mouse models carrying the I26T and R160C substitutions in the transcriptional repressor 
HESX1 as models for septo-optic dysplasia and hypopituitarism. Dis. Model. Mech. 1, 241–254. 
Sbrogna, J. L., Barresi, M. J. . and Karlstrom, R. O. (2003). Multiple roles for Hedgehog signaling 
in zebrafish pituitary development. Dev. Biol. 254, 19–35. 
Sheng, H. Z., Zhadanov, A. B., Mosinger, B., Fujii, T., Bertuzzi, S., Grinberg, A., Lee, E. J., 
Huang, S. P., Mahon, K. A., Westphal, H., et al. (1996). Specification of pituitary cell 
lineages by the LIM homeobox gene Lhx3. Science 272, 1004–7. 
Sheng, H. Z., Moriyama, K., Yamashita, T., Li, H., Potter, S. S., Mahon, K. A. and Westphal, H. 
(1997). Multistep control of pituitary organogenesis. Science 278, 1809–12. 
Shimogori, T., Lee, D. a, Miranda-Angulo, A., Yang, Y., Wang, H., Jiang, L., Yoshida, A. C., 
Kataoka, A., Mashiko, H., Avetisyan, M., et al. (2010). A genomic atlas of mouse 
hypothalamic development. Nat. Neurosci. 13, 767–775. 
Suga, H., Kadoshima, T., Minaguchi, M., Ohgushi, M., Soen, M., Nakano, T., Takata, N., 
Wataya, T., Muguruma, K., Miyoshi, H., et al. (2011). Self-formation of functional 
adenohypophysis in three-dimensional culture. Nature 480, 57–62. 
	 24	
Suh, H., Gage, P. J., Drouin, J. and Camper, S. A. (2002). Pitx2 is required at multiple stages of 
pituitary organogenesis: pituitary primordium formation and cell specification. Development 
129, 329–37. 
Tajima, T., Ohtake, A., Hoshino, M., Amemiya, S., Sasaki, N., Ishizu, K. and Fujieda, K. (2009). 
OTX2 Loss of Function Mutation Causes Anophthalmia and Combined Pituitary Hormone 
Deficiency with a Small Anterior and Ectopic Posterior Pituitary. J. Clin. Endocrinol. Metab. 
94, 314–319. 
Takuma, N., Sheng, H. Z., Furuta, Y., Ward, J. M., Sharma, K., Hogan, B. L., Pfaff, S. L., 
Westphal, H., Kimura, S. and Mahon, K. A. (1998). Formation of Rathke’s pouch requires 
dual induction from the diencephalon. Development 125, 4835–40. 
Tefft, J. D., Lee, M., Smith, S., Leinwand, M., Zhao, J., Bringas, P., Crowe, D. L. and 
Warburton, D. (1999). Conserved function of mSpry-2, a murine homolog of Drosophila 
sprouty, which negatively modulates respiratory organogenesis. Curr. Biol. 9, 219–22. 
Treier, M., Gleiberman, A. S., O’Connell, S. M., Szeto, D. P., McMahon, J. A., McMahon, A. P. 
and Rosenfeld, M. G. (1998). Multistep signaling requirements for pituitary organogenesis in 
vivo. Genes Dev. 12, 1691–704. 
Treier, M., O’Connell, S., Gleiberman,  a, Price, J., Szeto, D. P., Burgess, R., Chuang, P. T., 
McMahon,  a P. and Rosenfeld, M. G. (2001). Hedgehog signaling is required for pituitary 
gland development. Development 128, 377–386. 
Trowe, M.-O., Zhao, L., Weiss, A.-C., Christoffels, V., Epstein, D. J. and Kispert, A. (2013). 
Inhibition of Sox2-dependent activation of Shh in the ventral diencephalon by Tbx3 is required 
for formation of the neurohypophysis. Development 140, 2299–2309. 
Turner, N. and Grose, R. (2010). Fibroblast growth factor signalling: from development to cancer. 
Nat. Rev. Cancer 10, 116–129. 
Uhmann, A., Dittmann, K., Nitzki, F., Dressel, R., Koleva, M., Frommhold, A., Zibat, A., 
Binder, C., Adham, I., Nitsche, M., et al. (2007). The Hedgehog receptor Patched controls 
lymphoid lineage commitment. Blood 110, 1814–23. 
Vankelecom, H. (2010). Pituitary stem/progenitor cells: embryonic players in the adult gland? Eur. J. 
Neurosci. 32, 2063–2081. 
Xavier, G.M., Seppala, M., Barrell, W., Birjandi, A.A., Geoghegan, F., Cobourne, M.T. (2016). 
Hedgehog receptor function during craniofacial development. Dev. Biol. 415, 198-215. 
Wang, Y., Martin, J. F. and Bai, C. B. (2010). Direct and indirect requirements of Shh/Gli signaling 
in early pituitary development. Dev. Biol. 348, 199–209. 
Wang, F., Flanagan, J., Su, N., Wang, L.-C., Bui, S., Nielson, A., Wu, X., Vo, H.-T., Ma, X.-J. 
and Luo, Y. (2012). RNAscope: a novel in situ RNA analysis platform for formalin-fixed, 
paraffin-embedded tissues. J. Mol. Diagn. 14, 22–9. 
Wolf, B. B., Schuler, M., Echeverri, F. and Green, D. R. (1999). Caspase-3 is the primary activator 
of apoptotic DNA fragmentation via DNA fragmentation factor-45/inhibitor of caspase-activated 
DNase inactivation. J. Biol. Chem. 274, 30651–6. 
	 25	
Zhao, Y., Morales, D. C., Hermesz, E., Lee, W.-K., Pfaff, S. L. and Westphal, H. (2006). Reduced 
expression of the LIM-homeobox gene Lhx3 impairs growth and differentiation of Rathke’s 
pouch and increases cell apoptosis during mouse pituitary development. Mech. Dev. 123, 605–
613. 
Zhao, L., Zevallos, S. E., Rizzoti, K., Jeong, Y., Lovell-Badge, R. and Epstein, D. J. (2012). 
Disruption of SoxB1-dependent Sonic hedgehog expression in the hypothalamus causes septo-
optic dysplasia. Dev. Cell 22, 585–96. 
 
 
FIGURE LEGENDS 
 
Fig. 1. Expression of Shh/SHH, Gli1 and Ptch1 during normal pituitary development. In situ 
hybridisation and immunofluorescence on wild-type mid-sagittal (A-E, G-K, M-Q, S-W) and frontal 
sections (F,L,R,X) during pituitary organogenesis between 9.5 and 18.5 dpc. (A-F) Shh transcripts are 
detected in the anterior hypothalamus (AH, arrows), posterior hypothalamus (PH, asterisks) and 
pharyngeal endoderm (PE, arrowhead) abutting the developing Rathke’s pouch (RP). Note the 
expression in the subventricular zone around the 3rd ventricle (3v). (G-L) SHH immunostaining is 
observed in a similar pattern. Note the weak SHH signal in the anterior region of RP at 10.5 dpc (H, 
asterisk). Single SHH+ve cells are detected at 18.5 dpc in the AP (arrows) and overlying 
hypothalamus (asterisk in L). (M-R) In situ hybridisation against Gli1. Note that the expression of 
Gli1 in the developing RP (M-O, arrowheads), periluminal epithelium (P,Q, arrowheads) and 
marginal zone of the anterior pituitary (R, arrowhead). Within the hypothalamus, Gli1 transcripts are 
initially detected in the AH (M, arrow), but become restricted to the PH from 10.5 dpc (N-P, 
asterisks) and subventricular zone of the 3rd ventricle at 18.5 dpc (asterisk in R). (S-X) Ptch1 
transcripts are observed in the AH (arrows), PH (asterisks) and around the 3rd ventricle (asterisk in X). 
Within RP, Ptch1 is initially expressed in the rostral region of the evaginating RP at 9.5 dpc 
(arrowhead in the inset in S), at the boundary of RP with oral ectoderm and pharyngeal endoderm 
(arrowheads in T) and ventral region of the pinched-off pouch (arrowhead in U). Subsequently, Ptch1 
transcripts are localised within the periluminal epithelium and marginal zone (arrowheads in V-X). 
Abbreviations: RP, Rathke’s pouch; PH, posterior hypothalamus; AH, anterior hypothalamus; AP, 
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anterior pituitary; PP Posterior pituitary; IF, infundibulum; OE, oral endoderm; PE pharyngeal 
endoderm; 3v, third ventricle. Scale bar is 100µm.   
 
Fig. 2. Developmental arrest and loss of pituitary tissue in Hesx1Cre/+;Shhfl/- mutants by 12.5 dpc. 
Haematoxylin and eosin (H&E) staining on mid-sagittal sections of Hesx1Cre/+;Shhfl/- mutants and 
control embryos. (A,B) The evaginating RP (arrowheads) is observable in both genotypes at 9.5 dpc, 
but it looks smaller and not intimately associated to the overlying neural ectoderm in the mutant 
compared with the control embryo. (C,D) RP is clearly hypoplastic in the Hesx1Cre/+;Shhfl/- mutant 
relative to the control embryo at 10.5 dpc (arrowheads). (E-F) The mutant RP is severely hypoplastic, 
has not detached form the oral ectoderm and does not make contact with the overlying hypothalamus 
compared with the control RP (arrowheads). Note the lack of infundibulum (INF, arrow in E) in the 
mutant embryo. (G,H) Note the complete loss of pituitary tissue in the mutant relative to the control 
embryo (arrowhead). Abbreviations as in Fig. 1. Scale bar is 100µm.  
 
Fig. 3. Loss of expression of hypothalamic factors in Hesx1Cre/+;Shhfl/-  mutants at 18.5 dpc. In 
situ hybridisation against the hypothalamic factors somatostatin (Ss), growth hormone-releasing 
hormone (Ghrh), gonadotrophin-releasing hormone (Gnrh), proopiomelanocortin (Pomc1), arginine-
vassopressin (Avp) and Oxytocin (Ot) on frontal sections of Hesx1Cre/+;Shhfl/-  and control embryos at 
18.5 dpc. (A) Schematic representation of the plane of section indicating the positions of the anterior 
periventricular (aPV) and arcuate (arc) nuclei. (B-I) Note the loss of expression of Ss, Ghrh, Gnrh and 
Pomc1 in the mutants. (J) Schematic representation of the plane of section showing the approximate 
location of the supraoptic (SON) and paraventricular (PVN) nuclei. (K-N) Note the severe reduction 
in Avp and absence of Ot expression in the mutants compared with the control embryos. 
Abbreviations: aPV, anterior periventricular nuclei; Arc, arcuate nuclei; PVN, paraventricular nuclei; 
SON, supraoptic nuclei; 3V, third ventricle. Scale bar: 100µm 
 
Fig. 4. Loss of Shh expression in the anterior hypothalamus of Hesx1Cre/+;Shhfl/- mutants results 
in reduced Gli1 and Ptch1 expression in the developing Rathke’s pouch. In situ hybridisation 
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against Shh and anti-SHH immunofluorescent staining on mid-sagittal sections of control and 
Hesx1Cre/+;Shhfl/- mutant embryos at 9.5 and 10.5 dpc. (A-G) Expression of Shh transcripts (A,B,E,F) 
or SHH protein (C,D,G,H) is detected in the anterior and posterior hypothalamus in the control 
embryos, but is completely undetectable in the AH in the mutant embryos (AH, arrows and PH, 
arrowheads). Shh/SHH expression is not detected in the developing RP in the control embryos, but 
there is ectopic Shh/SHH signal in the posterior region of the developing RP adjacent to the 
pharyngeal endoderm (PE, red arrowhead) in the mutant RP. (I,J) Gli1 transcripts are strongly 
detected in the control RP (arrowhead in I), but barely detectable and mostly restricted to the posterior 
region in the mutant RP (arrowhead in J). Note the Gli1 expression in head mesenchyme underlying 
the AH in the mutant (asterisk in J). (K,L) Ptch1 expression is lost in the AH (arrow) and developing 
RP (arrowhead) in the mutant relative to the control embryo. (M,N) Shh transcripts are not detected in 
the anterior hypothalamus in the mutant embryo (arrows), but are detected throughout the oral 
ectoderm and pharyngeal endoderm in both the mutant and control embryos (arrowhead). 
Abbreviations as in Fig. 1. Scale bar is 100 µm.    
 
Fig. 5. Anterior hypothalamic identity is lost in Hesx1Cre/+;Shhfl/-  mutant embryos. In situ 
hybridisation and immunofluorescence on mid-sagittal sections at 10.5 dpc of control and 
Hesx1Cre/+;Shhfl/-  mutant embryos. (A-D) Fgf8 and Bmp4 expression domains are restricted to the 
posterior hypothalamus (PH) in the control embryos (arrow in A,C), but are remarkably anteriorised 
in the mutants (arrow in B,D). Note the ectopic expression of Bmp4 in the anterior region of the 
mutant Rathke’s pouch (RP) (arrowhead in D). (E-H) Tbx2 and Tbx3 transcripts are detected in the 
hypothalamus, in the region overlying RP (possibly the prospective infundibulum). Note the 
expression of these markers in the head mesenchyme underlying the hypothalamus (asterisk) and the 
separation between RP and the prospective infundibular area in the mutant embryo (arrowhead in F).  
(I,J) The expression domain of Nkx2.1 is shorter in the mutant compare with the control embryo 
(arrow). (K,L) Pomc1 transcripts are lost in the mutant AH compared with the control (arrows). 
(M,N) The Wnt5a expression domain is reduced in the mutant AH compared with the control 
(arrows). (O,P) TCF4 is expressed in the AH in the control embryo, but its expression is markedly 
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reduced in the mutant (arrows). Note the TCF4 ectopic expression in the posterior region of RP 
(arrowhead in P). (Q,R) In the control embryo (Q), immunostaining against OTX2 shows expression 
in the posterior hypothalamus (arrow) and ventral telencephalon (arrowhead), but no signal is 
observed in the AH (asterisk). In the mutant embryo (R), the OTX2-negative neuroepithelium is lost 
and the PH and VT domains are merged (arrow in R). (S,T) Immunolabelling revealing a lack of 
ISL1+ve cells in the mutant compared with the control AH (arrows). Note the presence of ISL1+ve 
cells in both the mutant and control RP (arrowheads). (U,V) Double immunofluorescence against N- 
and E-cadherin (green and red, respectively) showing comparable N-cadherin expression in the 
hypothalamus between both genotypes (arrows). Note that N-cadherin is not expressed in the anterior 
region of the mutant RP, which expresses E-cadherin instead, possibly suggesting a posterior 
expansion of its expression domain in the oral ectoderm (arrowhead in V). (W,X) SOX2 expression in 
the hypothalamus and RP epithelium is comparable between the control and mutant embryo. 
Abbreviations as in Fig. 1. Scale bar is 100µm. 
 
Fig. 6. RP epithelium fails to activate LHX3 and LHX4 expression in Hesx1Cre/+;Shhfl/-  mutants. 
Immunofluorescence and in situ hybridisation on mid-sagittal sections on Hesx1Cre/+;Shhfl/-  and 
control embryos against RP progenitor markers. Markers and stages are indicated. (A-L) Single 
immunofluorescent staining showing that while PITX1 expression is maintained, LHX3 is 
undetectable in the RP of the mutants compared to control embryos from 9.5-11.5dpc (arrowheads). 
(M-P) In situ hybridization confirms the lack of Lhx3 and Lhx4 expression in the mutant RP at 10.5 
dpc (arrowheads). (Q-X) Transcripts for other RP markers such as Pitx2, Six3, Pax6 and Wnt4 are 
detected in the developing mutant and control RP (arrowheads). Abbreviations as in Fig. 1. Scale bar 
is 100µm.   
 
Fig. 7. Reduced proliferation of RP epithelium in Hesx1Cre/+;Shhfl/- mutant embryos. (A-G) 
Immunofluorescent staining against phospho-Histone H3 (pHH3) on mid-sagittal sections of control 
and Hesx1Cre/+;Shhfl/- embryos from 9.5 to 11.5 dpc. Note a significant decrease in the mitotic index in 
the RP epithelium Hesx1Cre/+;Shhfl/- mutant compared with control embryos at 11.5dpc. The mitotic 
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index is the ratio of pHH3+ve cells out of the total DAPI+ve nuclei. Students T-Test: 9.5 dpc, p=0.92; 
10.5 dpc, p=0.0645; 11.5 dpc, p<0.001 (n=6 embryos per group). (H-M) Immunofluorescence against 
activated cleaved-Caspase 3 revealing the absence of positive cells in RP epithelium in both 
genotypes from 9.5 and 10.5 dpc. Apoptotic cells are observed only in the “feet” of the evaginating 
RP at 11.5 dpc (arrowheads). Mesenchymal cells around RP show reduced staining in the mutant 
embryo. Positive signal in the cavities is artefactual. Dashed lines delineate the area that was 
quantified. Abbreviations as in Fig. 1. Scale bars are 100µm. 
 
Fig. 8. Conditional deletion of Ptch1 in Hesx1Cre/+;Ptch1fl/fl mutants results in pituitary 
hyperplasia. (A-H) Haematoxylin and eosin (H&E) staining on mid-sagittal (A-F) and coronal (G,H) 
sections of control and Hesx1Cre/+;Ptch1fl/fl embryos throughout pituitary organogenesis. At 10.5 dpc 
(A,B), the morphology of the RP is comparable between genotypes, but looks slightly expanded in the 
mutant compared with the control embryo at 12.5 dpc (C,D). By 14.5 dpc (E,F), the 
Hesx1Cre/+;Ptch1fl/fl anterior pituitary (AP) is clearly hyperplastic relative to the control, but the  
infundibulum looks normal (INF). AP hyperplasia is also evident at 18.5 dpc (G,H) with dorsal 
extensions of the cleft. The posterior pituitary (PP) looks comparable between genotypes. Note the 
expansion of the marginal zone (MZ; arrowheads in G,H), which is thicker in the mutant compared 
with the control pituitary. G’ and H’ are insets of the boxed area in G and H. (I-P) In situ 
hybridisation against Gli1. A remarkable increase in Gli1 expression is observed throughout the AP in 
the mutants relative to the control embryos, including the MZ (arrowheads in O and P). O’ and P’ are 
insets of the boxed area in O and P. Abbreviations as in Fig. 1. Scale bar is 100µm.  
 
Fig. 9.  Increased numbers of SOX2+ve and SOX9+ cells and enhanced clonogenic potential in 
Hesx1Cre/+;Ptch1fl/fl  mutant pituitaries. Immunofluorescence against SOX2 and SOX9 on mid-
sagittal (A,B,E,F) and frontal (C,D,G,H) sections of control and Hesx1Cre/+;Ptch1fl/fl mutant embryos 
at 14.5 and 18.5 dpc. (A-D) SOX2 expression is comparable between genotypes at 14.5 dpc, but is 
clearly expanded in the Hesx1Cre/+;Ptch1fl/fl  pituitary relative to the control at 18.5 dpc. Note the 
thicker marginal zone in the mutant (arrowheads in C’ and D’)  (arrowheads). (C’,D’) Higher 
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magnification of the boxed region shown in C and D. (E-H) An expansion in SOX9 expression is 
observed in the mutant relative to the control pituitary at both 14.5 and 18.5 dpc. (G’,H’) Higher 
magnification of the boxed region shown in G and H. (I,J) Quantitative analysis confirms the 
expansion of the SOX2+ve and SOX9+ve cell compartment at 18.5 dpc. (K) Quantification of the 
clonogenic potential of the pituitary in Hesx1Cre/+;Ptch1fl/fl  mutants and control embryos at 18.5 dpc. 
A significant 3.4 fold increase is observed in the mutant pituitaries (n=6, p<0.01; bars represent 
means ± SD, Student’s T-test). Scale bars are 100µm. 
 
Fig. 10.  Failure to activate Lhx3 and Lhx4 expression in the developing RP of Nk2.1-/- mutants. 
Haematoxylin and eosin (H&E) and RNA in situ hybridisation on mid-sagittal sections of Nkx2.1-/- 
mutants and Nkx2.1+/+ control embryos at 10.5 dpc. (A,B) Note that Rathke’s pouch (RP) is 
hypoplastic in the Nkx2.1-/- mutant compared with the Nkx2.1+/+ control (arrowheads) and does not 
contact the overlying hypothalamus. (C-D) Shh transcripts are detected in the hypothalamus, but the 
expression domain is posteriorised in the mutant relative to the control embryo (arrows). Note the 
ectopic expression of Shh in the posterior region of RP in the mutant compared with the control 
embryo (arrowheads), suggesting an anteriorisation of the Shh expression domain in the pharyngeal 
endoderm (PE). (E-H) Fgf8 and Bmp4 expression domains in the posterior hypothalamus are 
completely lost in the mutant embryos (arrows). (I-L) In situ hybridisation revealing the total absence 
of both Lhx3 and Lhx4 expression in the RP of the mutants (arrowheads). (M-P) Immunostaining 
confirms the lack of LHX3 expression and reveals the expression of PITX1 in the mutant pituitary 
(arrowheads). Abbreviations as in Fig. 1.  Scale bar: 100µm. 
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Fig. 1. Expression of Shh/SHH, Gli1 and Ptch1 during normal pituitary development. In situ hybridisation and immuno-
fluorescence on wild-type mid-sagittal (A-E, G-K, M-Q, S-W) and frontal sections (F,L,R,X) during pituitary organogenesis 
between 9.5 and 18.5 dpc. (A-F) Shh transcripts are detected in the anterior hypothalamus (AH, arrows), posterior hypothala-
mus (PH, asterisks) and pharyngeal endoderm (PE, arrowhead) abutting the developing Rathke’s pouch (RP). Note the expres-
sion in the subventricular zone around the 3rd ventricle (3v). (G-L) SHH inmunostaining is observed in a similar pattern. Note 
the weak SHH signal in the anterior region of RP at 10.5 dpc (H, asterisk). Single SHH+ve cells are detected at 18.5 dpc in the 
AP (arrows) and overlying hypothalamus (asterisk in L). (M-R) In situ hybridisation against Gli1. Note that the expression 
of Gli1 in the developing RP (M-O, arrowheads), periluminal epithelium (P,Q, arrowheads) and marginal zone of the anterior 
pituitary (R, arrowhead). Within the hypothalamus, Gli1 transcripts are initially detected in the AH (M, arrow), but become 
restricted to the PH from 10.5 dpc (N-P, asterisks) and subventricular zone of the 3rd ventricle at 18.5 dpc (asterisk in R). (S-
X) Ptch1 transcripts are observed in the AH (arrows), PH (asterisks) and around the 3rd ventricle (asterisk in X). Within RP, 
Ptch1 is initially expressed in the rostral region of the evaginating RP at 9.5 dpc (arrowhead in the inset in S), at the boundary 
of RP with oral ectoderm and pharyngeal endoderm (arrowheads in T) and ventral region of the pinched-off pouch (arrow-
head in U). Subsequently, Ptch1 transcripts are localised within the periluminal epithelium and marginal zone (arrowheads in 
V-X). Abbreviations: RP, Rathke’s pouch; PH, posterior hypothalamus; AH, anterior hypothalamus; AP, anterior pituitary; PP 
Posterior pituitary; IF, infundibulum; OE, oral endoderm; PE pharyngeal endoderm; 3v, third ventricle. Scale bar is 100μm.  
Fig. 2. Developmental arrest and loss of pituitary 
tissue in Hesx1Cre/+;Shhfl/- mutants by 12.5 dpc. 
Haematoxylin and eosin (H&E) staining on mid-
sagittal sections of Hesx1Cre/+;Shhfl/- mutants and control 
embryos. (A,B) The evaginating RP (arrowheads) is 
observable in both genotypes at 9.5 dpc, but it looks 
smaller and not intimately associated to the overlying 
neural ectoderm in the mutant compared with the 
control embryo. (C,D) RP is clearly hypoplastic in the 
Hesx1Cre/+;Shhfl/- mutant relative to the control embryo at 
10.5 dpc (arrowheads). (E-F) The mutant RP is severely 
hypoplastic, has not detached form the oral ectoderm and 
does not make contact with the overlying hypothalamus 
compared with the control RP (arrowheads). Note the 
lack of infundibulum (INF, arrow in E) in the mutant 
embryo. (G,H) Note the complete loss of pituitary tissue 
in the mutant relative to the control embryo (arrowhead). 
Abbreviations as in Fig. 1. Scale bar is 100μm. 
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Fig. 3. Loss of expression of hypothalamic factors in Hesx1Cre/+;Shhfl/-  mutants at 18.5 dpc. In situ hybridisation 
against the hypothalamic factors somatostatin (Ss), growth hormone-releasing hormone (Ghrh), gonadotrophin-releasing 
hormone (Gnrh), proopiomelanocortin (Pomc1), arginine-vassopressin (Avp) and Oxytocin (Ot) on frontal sections of 
Hesx1Cre/+;Shhfl/-  and control embryos at 18.5 dpc. (A) Schematic representation of the plane of section indicating the 
positions of the anterior periventricular (aPV) and arcuate (arc) nuclei. (B-I) Note the loss of expression of Ss, Ghrh, Gnrh 
and Pomc1 in the mutants. (J) Schematic representation of the plane of section showing the approximate location of the 
supraoptic (SON) and paraventricular (PVN) nuclei. (K-N) Note the severe reduction in Avp and absence of Ot expression 
in the mutants compared with the control embryos. Abbreviations: aPV, anterior periventricular nuclei; Arc, arcuate nuclei; 
PVN, paraventricular nuclei; SON, supraoptic nuclei; 3V, third ventricle. Scale bar: 100μm
Fig. 4. Loss of Shh expression in the 
anterior hypothalamus of Hesx1Cre/+;Shhfl/- 
mutants results in reduced Gli1 and Ptch1 
expression in the developing Rathke’s 
pouch. In situ hybridisation against Shh 
and anti-SHH immunofluorescent staining 
on mid-sagittal sections of control and 
Hesx1Cre/+;Shhfl/- mutant embryos at 9.5 and 
10.5 dpc. (A-G) Expression of Shh transcripts 
(A,B,E,F) or SHH protein (C,D,G,H) 
is detected in the anterior and posterior 
hypothalamus in the control embryos, but 
is completely undetectable in the AH in 
the mutant embryos (AH, arrows and PH, 
arrowheads). Shh/SHH expression is not 
detected in the developing RP in the control 
embryos, but there is ectopic Shh/SHH signal 
in the posterior region of the developing RP 
adjacent to the pharyngeal endoderm (PE, 
red arrowhead) in the mutant RP. (I,J) Gli1 
transcripts are strongly detected in the control 
RP (arrowhead in I), but barely detectable 
and mostly restricted to the posterior region 
in the mutant RP (arrowhead in J). Note 
the Gli1 expression in head mesenchyme 
underlying the AH in the mutant (asterisk 
in J). (K,L) Ptch1 expression is lost in the 
AH (arrow) and developing RP (arrowhead) 
in the mutant relative to the control embryo. 
(M,N) Shh transcripts are not detected in the 
anterior hypothalamus in the mutant embryo 
(arrows), but are detected throughout the oral 
ectoderm and pharyngeal endoderm in both 
the mutant and control embryos (arrowhead). 
Abbreviations as in Fig. 1. Scale bar is 100 
μm.   
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Fig. 5. Anterior hypothalamic identity is lost in Hesx1Cre/+;Shhfl/-  mutant embryos. In situ hybridisation and immunofluorescence on mid-sagittal sections 
at 10.5 dpc of control and Hesx1Cre/+;Shhfl/-  mutant embryos. (A-D) Fgf8 and Bmp4 expression domains are restricted to the posterior hypothalamus (PH) 
in the control embryos (arrow in A,C), but are remarkably anteriorised in the mutants (arrow in B,D). Note the ectopic expression of Bmp4 in the anterior 
region of the mutant Rathke’s pouch (RP) (arrowhead in D). (E-H) Tbx2 and Tbx3 transcripts are detected in the hypothalamus, in the region overlying RP 
(possibly the prospective infundibulum). Note the expression of these markers in the head mesenchyme underlying the hypothalamus (asterisk) and the 
separation between RP and the prospective infundibular area in the mutant embryo (arrowhead in F).  (I,J) The expression domain of Nkx2.1 is shorter in 
the mutant compare with the control embryo (arrow). (K,L) Pomc1 transcripts are lost in the mutant AH compared with the control (arrows). (M,N) The 
Wnt5a expression domain is reduced in the mutant AH compared with the control (arrows). (O,P) TCF4 is expressed in the AH in the control embryo, but its 
expression is markedly reduced in the mutant (arrows). Note the TCF4 ectopic expression in the posterior region of RP (arrowhead in P). (Q,R) In the control 
embryo (Q), immunostaining against OTX2 shows expression in the posterior hypothalamus (arrow) and ventral telencephalon (arrowhead), but no signal is 
observed in the AH (asterisk). In the mutant embryo (R), the OTX2-negative neuroepithelium is lost and the PH and VT domains are merged (arrow in R). 
(S,T) Immunolabelling revealing a lack of ISL1+ve cells in the mutant compared with the control AH (arrows). Note the presence of ISL1+ve cells in both 
the mutant and control RP (arrowheads). (U,V) Double immunofluorescence against N- and E-cadherin (green and red, respectively) showing comparable 
N-cadherin expression in the hypothalamus between both genotypes (arrows). Note that N-cadherin is not expressed in the anterior region of the mutant RP, 
which expresses E-cadherin instead, possibly suggesting a posterior expansion of its expression domain in the oral ectoderm (arrowhead in V). (W,X) SOX2 
expression in the hypothalamus and RP epithelium is comparable between the control and mutant embryo. Abbreviations as in Fig. 1. Scale bar is 100μm.
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Fig. 6. RP epithelium fails to activate LHX3 and LHX4 expression in Hesx1Cre/+;Shhfl/-  mutants. Immunofluores-
cence and in situ hybridisation on mid-sagittal sections on Hesx1Cre/+;Shhfl/-  and control embryos against RP progenitor 
markers. Markers and stages are indicated. (A-L) Single immunofluorescent staining showing that while PITX1 ex-
pression is maintained, LHX3 is undetectable in the RP of the mutants compared to control embryos from 9.5-11.5dpc 
(arrowheads). (M-P) In situ hybridization confirms the lack of Lhx3 and Lhx4 expression in the mutant RP at 10.5 dpc 
(arrowheads). (Q-X) Transcripts for other RP markers such as Pitx2, Six3, Pax6 and Wnt4 are detected in the develop-
ing mutant and control RP (arrowheads). Abbreviations as in Fig. 1. Scale bar is 100μm.  
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Fig. 7. Reduced proliferation of RP epithelium in Hesx1Cre/+;Shhfl/- mutant embryos. (A-G) Immunofluorescent staining 
against phospho-Histone H3 (pHH3) on mid-sagittal sections of control and Hesx1Cre/+;Shhfl/- embryos from 9.5 to 11.5 dpc. 
Note a significant decrease in the mitotic index in the RP epithelium Hesx1Cre/+;Shhfl/- mutant compared with control embryos 
at 11.5dpc. The mitotic index is the ratio of pHH3+ve cells out of the total DAPI+ve nuclei. Students T-Test: 9.5 dpc, p=0.92; 
10.5 dpc, p=0.0645; 11.5 dpc, p<0.001 (n=6 embryos per group). (H-M) Immunofluorescence against activated cleaved-
Caspase 3 revealing the absence of positive cells in RP epithelium in both genotypes from 9.5 and 10.5 dpc. Apoptotic cells 
are observed only in the “feet” of the evaginating RP at 11.5 dpc (arrowheads). Mesenchymal cells around RP show reduced 
staining in the mutant embryo. Positive signal in the cavities is artefactual. Dashed lines delineate the area that was quantified. 
Abbreviations as in Fig. 1. Scale bars are 100μm.
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Fig. 8. Conditional deletion of Ptch1 in Hesx1Cre/+;Ptch1fl/fl mutants results in pituitary hyperplasia. (A-H) Haematoxylin 
and eosin (H&E) staining on mid-sagittal (A-F) and coronal (G,H) sections of control and Hesx1Cre/+;Ptch1fl/fl embryos 
throughout pituitary organogenesis. At 10.5 dpc (A,B), the morphology of the RP is comparable between genotypes, 
but looks slightly expanded in the mutant compared with the control embryo at 12.5 dpc (C,D). By 14.5 dpc (E,F), the 
Hesx1Cre/+;Ptch1fl/fl anterior pituitary (AP) is clearly hyperplastic relative to the control, but the  infundibulum looks normal 
(INF). AP hyperplasia is also evident at 18.5 dpc (G,H) with dorsal extensions of the cleft. The posterior pituitary (PP) looks 
comparable between genotypes. Note the expansion of the marginal zone (MZ; arrowheads in G,H), which is thicker in the 
mutant compared with the control pituitary. G’ and H’ are insets of the boxed area in G and H. (I-P) In situ hybridisation 
against Gli1. A remarkable increase in Gli1 expression is observed throughout the AP in the mutants relative to the control 
embryos, including the MZ (arrowheads in O and P). O’ and P’ are insets of the boxed area in O and P. Abbreviations as in 
Fig. 1. Scale bar is 100μm.
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Fig. 9.  Increased numbers of SOX2+ve and SOX9+ cells and enhanced clonogenic potential in Hesx1Cre/+;Ptch1fl/fl  mu-
tant pituitaries. Immunofluorescence against SOX2 and SOX9 on mid-sagittal (A,B,E,F) and frontal (C,D,G,H) sections of 
control and Hesx1Cre/+;Ptch1fl/fl mutant embryos at 14.5 and 18.5 dpc. (A-D) SOX2 expression is comparable between geno-
types at 14.5 dpc, but is clearly expanded in the Hesx1Cre/+;Ptch1fl/fl  pituitary relative to the control at 18.5 dpc. Note the thick-
er marginal zone in the mutant (arrowheads in C’ and D’)  (arrowheads). (C’,D’) Higher magnification of the boxed region 
shown in C and D. (E-H) An expansion in SOX9 expression is observed in the mutant relative to the control pituitary at both 
14.5 and 18.5 dpc. (G’,H’) Higher magnification of the boxed region shown in G and H. (I,J) Quantitative analysis confirms 
the expansion of the SOX2+ve and SOX9+ve cell compartment at 18.5 dpc. (K) Quantification of the clonogenic potential of 
the pituitary in Hesx1Cre/+;Ptch1fl/fl  mutants and control embryos at 18.5 dpc. A significant 3.4 fold increase is observed in the 
mutant pituitaries (n=6, p<0.01; bars represent means ± SD, Student’s T-test). Scale bars are 100μm.
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Fig. 10.  Failure to activate Lhx3 and Lhx4 expression in the developing RP of Nk2.1-/- mutants. Haematoxylin and 
eosin (H&E) and RNA in situ hybridisation on mid-sagittal sections of Nkx2.1-/- mutants and Nkx2.1+/+ control embryos at 
10.5 dpc. (A,B) Note that Rathke’s pouch (RP) is hypoplastic in the Nkx2.1-/- mutant compared with the Nkx2.1+/+ control 
(arrowheads) and does not contact the overlying hypothalamus. (C-D) Shh transcripts are detected in the hypothalamus, but 
the expression domain is posteriorised in the mutant relative to the control embryo (arrows). Note the ectopic expression 
of Shh in the posterior region of RP in the mutant compared with the control embryo (arrowheads), suggesting an 
anteriorisation of the Shh expression domain in the pharyngeal endoderm (PE). (E-H) Fgf8 and Bmp4 expression domains 
in the posterior hypothalamus are completely lost in the mutant embryos (arrows). (I-L) In situ hybridisation revealing the 
total absence of both Lhx3 and Lhx4 expression in the RP of the mutants (arrowheads). (M-P) Immunostaining confirms 
the lack of LHX3 expression and reveals the expression of PITX1 in the mutant pituitary (arrowheads). Abbreviations as 
in Fig. 1.  Scale bar: 100μm.
